Biomarkers in Drug Development: A Handbook of Practice, Application, and Strategy
This price is valid for United States. Change location to view local pricing and availability.
Other Available Formats: E-book
PART I BIOMARKERS AND THEIR ROLES IN DRUG DEVELOPMENT.
1 Biomarkers Are Not New (Ian Dews).
2 Biomarkers: Facing the Challenges at the Crossroads of Research and Health Care (Gregory J. Downing).
3 Enabling Go/No Go Decisions (J. Fred Pritchard and Mallé Jurima-Romet).
PART II IDENTIFYING NEW BIOMARKERS: TECHNOLOGY APPROACHES.
4 Imaging as a Localized Biomarker: Opportunities and Challenges (Jonathan B. Moody, Philip S. Murphy, Edward P. Ficaro).
5 Protein Biomarker Discovery Using Mass Spectrometry-Based Proteomics (Joanna M. Hunter and Daniel Chelsky).
6 Quantitative Multiplexed Patterning of Immune-Related Biomarkers (Dominic Eisinger, Ralph McDade, and Thomas Joos).
7 Gene Expression Profiles as Preclinical and Clinical Cancer Biomarkers of Prognosis, Drug Response, and Drug Toxicity (Jason A. Sprowl and Amadeo M. Parissenti).
8 Use of High-Throughput Proteomic Arrays for the Discovery of Disease-Associated Molecules (Douglas M. Molina, W. John W. Morrow, and Xiaowu Liang).
PART III CHARACTERIZATION AND VALIDATION.
9 Characterization and Validation Biomarkers in Drug Development: Regulatory Perspective (Federico Goodsaid).
10 Fit-for-Purpose Method Validation and Assays for Biomarker Characterization to Support Drug Development (Jean W. Lee, Yuling Wu, and Jin Wang).
11 Molecular Biomarkers from a Diagnostic Perspective (Klaus Lindpaintner).
12 Strategies for the Co-Development of Drugs and Diagnostics: FDA Perspective on Diagnostics Regulation (Francis Kalush and Steven Gutman).
13 Importance of Statistics in the Qualification and Application of Biomarkers (Mary Zacour).
PART IV BIOMARKERS IN DISCOVERY AND PRECLINICAL SAFETY.
14 Qualification of Safety Biomarkers for Application to Early Drug Development (William B. Mattes and Frank D. Sistare).
15 Development of Serum Calcium and Phosphorus as Clinical Biomarkers for Drug-Induced Systemic Mineralization: Case Study with a MEK Inhibitor (Alan P. Brown).
16 Biomarkers for the Immunogenicity of Therapeutic Proteins and its Clinical Consequences (Claire Cornips and Huub Shellekens).
17 New Markers of Kidney Injury (Sven A. Beushausen).
PART V TRANSLATING FROM PRECLINICAL RESULTS TO CLINICAL AND BACK.
18 Translational Medicine-A Paradigm Shift in Modern Drug Discovery and Development: The Role of Biomarkers (Giora Z. Feuerstein, Salvatore Alesci, Frank L. Walsh, J. Lynn Rutkowski, and Robert R. Ruffolo, Jr.).
19 Clinical Validation and Biomarker Translation (David Lin, Andreas Scherer, Raymond Ng, Robert Balshaw, Shawna Flynn, Paul Keown, Rob McMaster, and Bruce McManus).
20 Predicting and Assessing an Inflammatory Disease and Its Complications: Example from Rheumatoid Arthritis (Christina Trollmo and Lars Klareskog).
21 Pharmacokinetic and Pharmacodynamic Biomarker Correlations (J.F. Marier and Keith Gallicano).
22. Validating In Vitro Toxicity Biomarkers Against Clinical Endpoints (Calvert Louden and Ruth A. Roberts).
PART VI BIOMARKERS IN CLINICAL TRIALS.
23 Opportunities and Pitfalls Associated with Early Utilization of Biomarkers: A Case Study in Anticoagulant Development (Kay A. Criswell).
24 Integrating Molecular Testing into Clinical Applications (Anthony A. Killeen).
25 Biomarkers for Lysosomal Storage Disorders (Ari Zimran, Candida Fratazzi, and Deborah Elstein).
26 The Value Chain in the Development of Biomarkers for Disease Targets (Charles W. Richard III, Arthur O. Tzianabos, Whaijen Soo).
PART VII LESSONS LEARNED: PRACTICAL ASPECTS OF BIOMARKER IMPLEMENTATION.
27 Biomarkers in Pharmaceutical Development: The Essential Role of Project Management and Teamwork (Lena King, Mall‚ Jurima-Romet, and Nita Ichhpurani).
28 Integrating Academic Laboratories Into Pharmaceutical Development (Peter A. Ward and Kent J. Johnson).
29 Funding Biomarker Research and Development Through the Small Business Innovative Research Program (James Varani).
30 Novel and Traditional Nonclinical Biomarker Utilization in the Estimation of Pharmaceutical Therapeutic Indices (Bruce D. Car, Brian Gemzik, and William R. Foster).
31 Anti-Unicorn Principle: Appropriate Biomarkers Don’t Need to be Rare or Hard to Find (Michael R. Bleavins and Ramin Rahbari).
32 Biomarker Patent Strategies: Opportunities and Risks (Cynthia M. Bott and Eric J. Baude).
PART VIII WHERE ARE WE HEADING AND WHAT DO WE REALLY NEED?
33 IT Supporting Biomarker-Enabling Drug Development (Michael Hehenberger).
34 Redefining Disease and Pharmaceutical Targets Through Molecular Definitions and Personalized Medicine (Craig P. Webb, John F. Thompson and Bruce H. Littman).
35 Ethics of Biomarkers: The Borders of Investigative Research, Informed Consent, and Patient Protection (Heather Walmsley, Michael Burgess, Jacqui Brinkman, Richard Hegele, Janet Wilson-McManus, and Bruce McManus).
36 Pathodynamics: Improving Biomarker Selection By Getting More Information From Changes Over Time (Donald C. Trost).
37 Optimizing the Use of Biomarkers for Drug Development: A Clinician's Perspective (Alberto Gimona).
38 Nanotechnology-Based Biomarker Detection (Joshua Reinke).
Buy Both and Save 25%!
Biomarkers in Drug Development: A Handbook of Practice, Application, and Strategy (US $186.00)
Total List Price: US $301.00
Discounted Price: US $225.75 (Save: US $75.25)